Literature DB >> 21196322

MYCN, neuroblastoma and focal adhesion kinase (FAK).

Elizabeth A Beierle1.   

Abstract

Neuroblastoma is the most common extracranial solid tumor of childhood. This tumor is characterized by poor survival, especially when it features amplification of the MYCN oncogene. The ability for human cancers to propagate is marked by their ability to invade and metastasize to distant sites. Focal adhesion kinase (FAK) is a key tyrosine kinase involved in the survival and metastasis of a number of human tumor types. We have shown that FAK is present in human neuroblastoma and that its expression in neuroblastoma is related to the MYCN oncogene. We have also demonstrated that inhibition of FAK in neuroblastoma leads to decreased tumor cell survival. The current review addresses the relationship between the MYCN oncogene, focal adhesion kinase and neuroblastoma.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21196322      PMCID: PMC3171213          DOI: 10.2741/e257

Source DB:  PubMed          Journal:  Front Biosci (Elite Ed)        ISSN: 1945-0494


  54 in total

1.  Decrease of proliferation rate and induction of differentiation by a MYCN antisense DNA oligomer in a human neuroblastoma cell line.

Authors:  A Negroni; S Scarpa; A Romeo; S Ferrari; A Modesti; G Raschellà
Journal:  Cell Growth Differ       Date:  1991-10

Review 2.  c-Myc and apoptosis.

Authors:  G Packham; J L Cleveland
Journal:  Biochim Biophys Acta       Date:  1995-07-28

3.  Association of focal adhesion kinase with its potential substrate phosphatidylinositol 3-kinase.

Authors:  H C Chen; J L Guan
Journal:  Proc Natl Acad Sci U S A       Date:  1994-10-11       Impact factor: 11.205

4.  N-myc down regulates neural cell adhesion molecule expression in rat neuroblastoma.

Authors:  R Akeson; R Bernards
Journal:  Mol Cell Biol       Date:  1990-05       Impact factor: 4.272

5.  Differential regulation of focal adhesion kinase and mitogen-activated protein kinase tyrosine phosphorylation during insulin-like growth factor-I-mediated cytoskeletal reorganization.

Authors:  B Kim; E L Feldman
Journal:  J Neurochem       Date:  1998-09       Impact factor: 5.372

6.  A small molecule inhibitor, 1,2,4,5-benzenetetraamine tetrahydrochloride, targeting the y397 site of focal adhesion kinase decreases tumor growth.

Authors:  Vita M Golubovskaya; Carl Nyberg; Min Zheng; Frederick Kweh; Andrew Magis; David Ostrov; William G Cance
Journal:  J Med Chem       Date:  2008-12-11       Impact factor: 7.446

7.  Inhibition of focal adhesion kinase and src increases detachment and apoptosis in human neuroblastoma cell lines.

Authors:  Elizabeth A Beierle; Xiaojie Ma; Angelica Trujillo; Elena V Kurenova; William G Cance; Vita M Golubovskaya
Journal:  Mol Carcinog       Date:  2010-03       Impact factor: 4.784

8.  Augmented MYCN expression advances the malignant phenotype of human neuroblastoma cells: evidence for induction of autocrine growth factor activity.

Authors:  L Schweigerer; S Breit; A Wenzel; K Tsunamoto; R Ludwig; M Schwab
Journal:  Cancer Res       Date:  1990-07-15       Impact factor: 12.701

9.  MYCN-mediated regulation of the MRP1 promoter in human neuroblastoma.

Authors:  Chitra F Manohar; James A Bray; Helen R Salwen; Janice Madafiglio; Andy Cheng; Claudia Flemming; Glenn M Marshall; Murray D Norris; Michelle Haber; Susan L Cohn
Journal:  Oncogene       Date:  2004-01-22       Impact factor: 9.867

10.  Cloning and characterization of the promoter region of human focal adhesion kinase gene: nuclear factor kappa B and p53 binding sites.

Authors:  Vita Golubovskaya; Aparna Kaur; William Cance
Journal:  Biochim Biophys Acta       Date:  2004-05-25
View more
  2 in total

1.  MycN promotes TRPM7 expression and cell migration in neuroblastoma through a process that involves polyamines.

Authors:  Ingo Lange; Dana-Lynn T Koomoa
Journal:  FEBS Open Bio       Date:  2014-10-30       Impact factor: 2.693

2.  Copy Number Analysis Reveal Genetic Risks of Penile Cancer.

Authors:  Yongbo Yu; Chengwen Gao; Yuanbin Chen; Meilan Wang; Jianfeng Zhang; Xiaocheng Ma; Shuaihong Liu; Hang Yuan; Zhiqiang Li; Haitao Niu
Journal:  Front Oncol       Date:  2020-12-14       Impact factor: 6.244

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.